These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3360965)

  • 21. Synthesis and in vitro antibacterial activity of a new series of monobactam derivatives.
    Valcavi U; Aveta R; Brandt A; Corsi GB; Bosone E; Farina P; Guazzi G
    Farmaco Sci; 1988 Jun; 43(6):559-66. PubMed ID: 3208898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and antimicrobial properties of substituted 3-aminoxypropionyl and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams.
    Balsamo A; Macchia B; Orlandini E; Rossello A; Macchia F; Broccali G; Fonio W
    Farmaco; 1990 Jul; 45(7-8):879-88. PubMed ID: 2282121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial activity in vitro of tigemonam, a new oral monobactam.
    Schito GC; Debbia E; Bandelloni R; Paglia P; Pesce A
    J Chemother; 1989 May; 1 Suppl 2():41-4. PubMed ID: 2809702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters.
    Mushtaq S; Warner M; Livermore D
    J Antimicrob Chemother; 2010 Feb; 65(2):266-70. PubMed ID: 19996139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth curve patterns of Escherichia coli, Serratia marcescens, and Proteus vulgaris submitted to different tigemonam concentrations.
    Yourassowsky E; van der Linden MP; Lismont MJ; Crokaert F
    J Chemother; 1989 May; 1 Suppl 2():49-53. PubMed ID: 2681561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative antibacterial activity of the new oral monobactam tigemonam (SQ 30836) against urinary isolates.
    Cocuzza G; Raimondi A
    J Chemother; 1989 Jul; 1(4 Suppl):126-8. PubMed ID: 16312335
    [No Abstract]   [Full Text] [Related]  

  • 27. Conjugation of Aztreonam, a Synthetic Monocyclic β-Lactam Antibiotic, to a Siderophore Mimetic Significantly Expands Activity Against Gram-Negative Bacteria.
    Liu R; Miller PA; Miller MJ
    ACS Infect Dis; 2021 Nov; 7(11):2979-2986. PubMed ID: 34668698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aztreonam: the first monobactam.
    Sykes RB; Bonner DP
    Am J Med; 1985 Feb; 78(2A):2-10. PubMed ID: 3871589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aztreonam: discovery and development of the monobactams.
    Sykes RB; Wells JS; Parker WL; Koster WH; Cimarusti CM
    N J Med; 1986 Jan; Spec No():8-15. PubMed ID: 3513063
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam.
    van Ogtrop ML; Guiot HF; Mattie H; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):983-5. PubMed ID: 1854181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active-Site Protonation States in an Acyl-Enzyme Intermediate of a Class A β-Lactamase with a Monobactam Substrate.
    Vandavasi VG; Langan PS; Weiss KL; Parks JM; Cooper JB; Ginell SL; Coates L
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties.
    Neu HC
    Rev Infect Dis; 1986; 8 Suppl 3():S237-59. PubMed ID: 3529320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A; Meyran M; Huerre M
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo evaluation of tigemonam, a novel oral monobactam.
    Clark JM; Olsen SJ; Weinberg DS; Dalvi M; Whitney RR; Bonner DP; Sykes RB
    Antimicrob Agents Chemother; 1987 Feb; 31(2):226-9. PubMed ID: 3551830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam.
    Jones RN; Barry AL; Thornsberry C; Fuchs PC; Packer RR
    Am J Clin Pathol; 1986 Nov; 86(5):608-18. PubMed ID: 3096130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
    Verbist L; Glupczynski Y
    Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effects of monobactams and carbapenems.
    Alván G; Nord CE
    Drug Saf; 1995 May; 12(5):305-13. PubMed ID: 7669260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The monobactams.
    Brewer NS; Hellinger WC
    Mayo Clin Proc; 1991 Nov; 66(11):1152-7. PubMed ID: 1943248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative in vitro activity of 6 recent beta-lactams against hospital strains of Acinetobacter calcoaceticus: role of the monobactam SQ 26,776].
    Joly-Guillou ML; Serieys C; Verin-Prevost C; Bergogne-Berezin E
    Pathol Biol (Paris); 1983 May; 31(5):392-5. PubMed ID: 6353329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.